|
| 37306759 | Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma. | Cancer Res | 2023 |
| 37350973 | Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma. | Front Immunol | 2023 |
| 35122833 | Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. | Pharmacol Ther | 2022 |
| 36620102 | Perioperative Challenges in the Management of Rhino-Orbital Cerebral Mucormycosis: An Observational Study from a Tertiary Care Hospital. | Anesth Essays Res | 2022 |
| 33480647 | Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma. | J Pediatr Hematol Oncol | 2021 |
| 33681757 | Incapacity in childbirth - Rare or common? | Eur J Obstet Gynecol Reprod Biol X | 2021 |
| 33872215 | Rapid Multiplex Loop-Mediated Isothermal Amplification (m-LAMP) Assay for Differential Diagnosis of Leprosy and Post-Kala-Azar Dermal Leishmaniasis. | Am J Trop Med Hyg | 2021 |
| 33669187 | BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma. | Cancers (Basel) | 2021 |
| 34557659 | The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma. | iScience | 2021 |
| 34219438 | Development of a novel loop-mediated isothermal amplification assay for rapid detection of Mycobacterium leprae in clinical samples. | Indian J Dermatol Venereol Leprol | 2021 |
| 32722460 | Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions. | Cancers (Basel) | 2020 |
| 31974273 | Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. | Mol Cancer Ther | 2020 |
| 32793389 | A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. | Cell Discov | 2020 |
| 32983125 | "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma. | Front Immunol | 2020 |
| 30853982 | Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. | J Oncol | 2019 |
| 30071568 | Erratum to: Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. | Thromb Haemost | 2019 |
| 31018997 | SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. | Mol Cancer Ther | 2019 |
| 29475942 | Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. | J Biol Chem | 2018 |
| 29847841 | Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. | Thromb Haemost | 2018 |
| 28817691 | Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype. | PLoS One | 2017 |
| 28137841 | Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. | Proc Natl Acad Sci U S A | 2017 |
| 26938241 | PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. | PLoS One | 2016 |
| 28881723 | Association of high microvessel α<sub>v</sub>β<sub>3</sub> and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. | Oncotarget | 2016 |
| 27496136 | Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. | Mol Cancer Ther | 2016 |
| 25578041 | Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. | Cancer Chemother Pharmacol | 2015 |
| 26257191 | Vascular remodeling underlies rebleeding in hemophilic arthropathy. | Am J Hematol | 2015 |
| 24162827 | PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. | J Neurooncol | 2014 |
| 25425962 | Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)â¿¿V-Ha-Ras transgenic mouse glioma model. | Cancer Cell Int | 2014 |
| 24982421 | MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. | J Biol Chem | 2014 |
| 25103499 | A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis. | Mol Cancer Res | 2014 |
| 24770346 | Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. | PLoS One | 2014 |
| 24886428 | A PKC-SHP1 signaling axis desensitizes Fcγ receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates FcγR mediated phagocytosis. | BMC Immunol | 2014 |
| 24881819 | PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. | Exp Cell Res | 2014 |
| 24309609 | Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. | J Pediatr Hematol Oncol | 2014 |
| 22906884 | Purification and characterization of phosphoenolpyruvate carboxykinase from Raillietina echinobothrida, a cestode parasite of the domestic fowl. | Parasitology | 2013 |
| 19756573 | Guanidine hydrochloride and urea-induced unfolding of Brugia malayi hexokinase. | Eur Biophys J | 2010 |
| 18456347 | Molecular cloning and characterization of Plasmodium falciparum transketolase. | Mol Biochem Parasitol | 2008 |
| 18499511 | Molecular cloning and characterization of Brugia malayi hexokinase. | Parasitol Int | 2008 |
| 18001110 | DNA binding and topoisomerase II inhibitory activity of water-soluble ruthenium(II) and rhodium(III) complexes. | Inorg Chem | 2007 |